FBR Capital Reiterates Market Perform Following Keryx Biopharma's (KERX) Recent Financing
Tweet Send to a Friend
FBR Capital reiterated a Market Perform rating and $10.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) following recent financing. Keryx ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
